Ohr Pharmaceutical closes SKS Ocular acquisition Ohr Pharmaceutical announced the closing of its previously announced acquisition of the assets of SKS Ocular. In connection with this transaction, three of the cofounders of SKS Ocular are being appointed to senior management and advisory roles at Ohr. Jason Slakter has been appointed Chief Medical Officer and is expected to join the Board of Directors. Glenn Stoller has been appointed Chief Scientific Officer. Peter Kaiser will serve as senior vice president of product development.